Arbutus Biopharma Corporation (LON:0SGC)

Market Cap	586.39M +14.9%
Revenue (ttm)	10.87M +116.6%
Net Income	-31.45M
EPS	-0.17
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	756
Average Volume	1,640
Open	3.280
Previous Close	3.309
Day's Range	3.280 - 3.319
52-Week Range	2.365 - 4.675
Beta	n/a
RSI	49.03
Earnings Date	Mar 5, 2026

About Arbutus Biopharma

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune res...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 44
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0SGC

Financial Performance

In 2024, Arbutus Biopharma's revenue was $6.17 million, a decrease of -65.98% compared to the previous year's $18.14 million. Losses were -$69.92 million, -4.02% less than in 2023.

Financial numbers in USD